Fosaprepitant May Lower Risk of Emesis, Nausea in Women With Cervical Cancer

Share this content:
Patients with cervical cancer who receive fosaprepitant in addition to palonosetron and dexamethasone may be less likely to experience emesis and nausea.
Patients with cervical cancer who receive fosaprepitant in addition to palonosetron and dexamethasone may be less likely to experience emesis and nausea.

Patients with cervical cancer who receive fosaprepitant in addition to palonosetron and dexamethasone may be less likely to experience emesis and nausea compared to those receiving palonosetron and dexamethasone alone, according to a study published in The Lancet Oncology.1

Researchers led by Christina Ruhlmann, PhD, of the Odense University Hospital in Denmark conducted a multinational, randomized, double-blind, placebo-controlled phase 3 trial of 234 women with cervical cancer who were scheduled to receive fractionated radiotherapy and weekly cisplatin for 5 weeks.

These patients were randomly assigned to receive either single doses of fosaprepitant intravenously or placebo in combination with palonosetron intravenously and dexamethasone orally before cisplatin administration.

The percentage of patients on fosaprepitant who sustained no emesis at 5 weeks was found to be 65.7% compared to 48.7% for those on placebo, with a significantly lower cumulative risk of emesis in the fosaprepitant group as well.

Treatments were found to be generally well-tolerated with few grade 3 adverse events, the most common being diarrhea, and none of which were related to the study treatment. There was only one report of a grade 4 adverse event of neutropenia in the fosaprepitant group.

RELATED: Co-testing May Detect Invasive Cervical Cancer Better Than HPV-only Screening

“To our knowledge, this is the first study to investigate safety and efficacy of a NK-1 receptor antagonist during 5 weeks of radiotherapy and concomitant weekly cisplatin,” the authors noted. “Further investigations in other radiotherapy settings are warranted.”

Reference

  1. Ruhlmann CH, Christensen TB, Dohn LH, et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial [published online ahead of print March 4, 2016]. Lancet Oncol. doi: 10.1016/S1470-2045(15)00615-4.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters